Multiple sclerosis is a chronic inflammatory and neurodegenerative disease characterized by demyelination. To follow patients longitudinally and monitor treatment response, there is a need for robust and tissue-specific imaging biomarkers reflective of the heterogeneous disease course. Here, we aimed to validate REMyDI as an MRI-based measure of myelin ex vivo and in vivo. Histopathologically, REMyDI correlates well with all three of the studied myelin staining methods. In vivo, REMyDI revealed a strong sensitivity in differentiating white matter as compared to normal appearing white matter with associations to both cognitive (information processing speed) and physical disability (Expanded Disability Status Scale).
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords